{"id":"imeglimin-reference-product","_chembl":null,"modality":"Small molecule","_dailymed":null,"mechanism":{"target":"Mitochondrial bioenergetics","explanation":"Imeglimin acts on mitochondria to restore cellular energy metabolism. It enhances insulin secretion from pancreatic beta cells, improves insulin sensitivity in peripheral tissues, and reduces hepatic glucose production through modulation of mitochondrial function.","oneSentence":"Imeglimin targets mitochondrial bioenergetics to improve glucose metabolism and insulin sensitivity."},"_scrapedAt":"2026-03-28T05:06:34.983Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779122999,"model":"claude-sonnet-4-5-20250929"},"competitors":[{"name":"metformin","brand":"Glucophage","company":null,"rationale":"First-line oral antidiabetic targeting glucose metabolism"},{"name":"sitagliptin","brand":"Januvia","company":"Merck","rationale":"Oral DPP-4 inhibitor for type 2 diabetes management"},{"name":"empagliflozin","brand":"Jardiance","company":"Boehringer Ingelheim","rationale":"Oral SGLT2 inhibitor for type 2 diabetes treatment"}],"description":"Imeglimin is a first-in-class oral antidiabetic agent developed by Poxel SA. It represents a novel therapeutic approach for type 2 diabetes through its unique mechanism targeting mitochondrial bioenergetics. The reference product formulation is being evaluated in Phase 1 clinical development.","indications":{"approved":[{"status":"investigational","condition":"Type 2 diabetes mellitus","patientPopulation":"Adult patients"}]},"trialDetails":[{"nctId":"NCT07127094","phase":"PHASE1","title":"Bioequivalence Assessment Between Two Imeglimin Hydrochloride Film Coated Tablet Formulations","status":"COMPLETED","sponsor":"Aya Mohammed Abdel Magid Abdel Hamid","startDate":"2025-03-09","conditions":"Bioequivalence Study in Healthy Subjects","enrollment":29},{"nctId":"NCT03646331","phase":"PHASE1","title":"Bioequivalence of Imeglimin Tablet Formulations","status":"COMPLETED","sponsor":"Poxel SA","startDate":"2018-09-03","conditions":"Bioequivalence","enrollment":16}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"Imeglimin Reference product","genericName":"Imeglimin Reference product","companyName":"Poxel SA","companyId":"poxel-sa","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}